Navigation Links
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
Date:8/24/2011

ce daily in the oral treprostinil group. Discontinuations due to adverse events were 18 (11%) and 5 (3%) in the treprostinil and placebo groups, respectively. Adverse events associated with discontinuations were typically prostacyclin-related effects including headache, nausea and vomiting.

Preliminary analysis of other secondary efficacy measures, including time to clinical worsening, change in combined 6MWD and Borg Dyspnea Score rating (shortness of breath test) and Dyspnea-Fatigue index, WHO functional class, and PAH signs and symptoms, did not differ significantly between oral treprostinil and placebo (p>0.05).

Further review and analysis of the FREEDOM-C(2) preliminary results are ongoing.  A summary of the preliminary analysis conducted thus far can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm beginning at 5:00 a.m. Eastern Time on August 24, 2011.  Full data from FREEDOM-C(2) will be presented at an upcoming medical meeting and will also be available through the publication of peer-reviewed journal articles.

"While we did not achieve a statistically significant result for this trial, we believe the positive results from our previously-announced FREEDOM-M study support an NDA filing of oral treprostinil in treatment naive patients," said Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer. "Given that treprostinil is already approved for use in PAH by subcutaneous, intravenous and inhaled routes of administration, we believe the data obtained from all FREEDOM trials support an NDA for oral treprostinil in this indication," added Dr. Jeffs. "We will now focus on completing the NDA for filing by the first half of 2012."

Conference Call

On Wednesday, August 24, 2011 at 9:00 a.m. United Therapeutics will host a one-hour conference call to answer questions related to FREEDOM-C(2).

<
'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
4. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat
11. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... United Kingdom -based Lab M Holdings, ... and diagnostic systems. Lab M was ... provider of microbial testing and diagnostic products for the ... company currently sells into more than 70 countries worldwide, ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2015. Biorem,s complete second quarter financial statements and MD&A have been ... except earnings per shareThree-months ended , Six -months endedJune 30 , ... , 2014 Revenue , 4,709 , ... , 1,656 , 56 , 3,188 ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... 10, 2011 Enobia Pharma Inc., today announced that ... ENB-0040, a bone targeted enzyme replacement therapy being investigated ... bone disorder. The results were presented by Robert Heft, ... the 29th Annual J.P. Morgan Healthcare Conference in San ...
... 10, 2011 Entrega, Inc., a new company ... formation by Enlight Biosciences, a Boston-based company established ... pharmaceutical companies. As part of its initial development ... drug delivery platform to create orally bioavailable formulations ...
... Aratana Therapeutics, a newly-formed company focused on the development of ... it has closed a $20 million Series A financing led ... we will be focused on taking advancements from the human ... and care for animals," said Dr. David Rosen, President and ...
Cached Biology Technology:Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 3New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 2New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 3
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... Synaptics, Inc. (Nasdaq: SYNA ), the ... members of the executive management team will present to ... Leadership Forum on Tuesday, August 11, 2015 at 1:00 ... the Sonnenalp Resort in Vail, CO. ... information. An audio webcast of the event will be ...
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... CAMBRIDGE, Mass., Oct. 20, 2010 -- Microbes living at the ... of the gaseous waste from the Deepwater Horizon oil spill ... miles of the spill site. A paper on that ... ago today, will appear in a forthcoming issue of the ...
... reducing the cost of certain catalysts substances that ... of super-strong forms of the world,s most widely used ... issue of Chemical & Engineering News (C&EN), ... led to availability of stronger, more durable consumer products ...
... BOSTON (October 20, 2010) - People who consume several ... of refined grains appear to have less of a type ... triggering cardiovascular disease and type 2 diabetes, a new study ... Center on Aging (USDA HNRCA) at Tufts University observed lower ...
Cached Biology News:Microbes may consume far more oil-spill waste than earlier thought 2Eating mostly whole grains, few refined grains linked to lower body fat 2
... expertise that made the original Gene Pulser apparatus ... available has been applied in the Gene Pulser ... modular design of the Gene Pulser II system ... that has the widest range of settings to ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... discovery system miniaturizes, integrates and automates ... LabChip technology, the LabChip 3000 performs ... flow fashion. LabChip assays are separations-based, ... what is achievable in homogenous, well-based ...
...
Biology Products: